Leadership
Compass Pathways, now leading the race toward regulatory approval for a classic psychedelic, mapped out its strategy behind what could become one of the industry’s more unconventional drug launches.
Chugai’s partnering office in South San Francisco advances the Japanese company’s business development activities in the US beyond its venture fund established in Boston in 2023.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Astellas head of oncology development on why a pan-KRAS degrader and a modality-first strategy could define the big pharma’s next chapter.
San Diego-based Onchilles Pharma's neutrophil-derived ELANE pathway agent N17350 targets a universal cancer vulnerability, combining direct tumor killing with immune activation. It is now entering first-in-human trials across solid tumors.
Merck's post-Keytruda oncology strategy rests on three pillars – immune deepening, tissue targeting and tumor-intrinsic mechanisms – anchored by patient selection, AI-accelerated discovery and a KRAS bet that could define its next era.
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
Praxis Precision Medicines is planning to shift from a clinical-stage company to a competitive commercial player in CNS, with the potential to launch multiple blockbuster medicines in the near future.
As India implements minimum import prices for certain antibiotics and key starting materials, Sandoz's Simon Goeller speaks to Generics Bulletin about the potential for Chinese suppliers to dominate the world market and weaponize supply.
Surgeon burnout is not a new phenomenon, but where it once was episodic, surgeons now report that it feels more sustained. Support structures have not kept pace, said Johnson & Johnson MedTech VP Africa Wallace on the release of a new study of causes, trends and issues arising.
A decade ago, China was buying Western drugs. Now it is selling them. Executives who ignore the shift do so at their peril.
After nearly 30 years at NASA, Omar Hatamleh prepares for his next chapter and fourth book on AI. He told Medtech Insight AI will speed up medical breakthroughs, extend life spans and bring AGI sooner than expected but also drive job losses, erode privacy and force humans to rethink their purpose.
As biopharma continues to push the boundaries of innovation, the most powerful breakthroughs are coming from the discovery of new drug modalities, the reinvention of old ones and a strategic application of multi-modality treatment regimens.
Twenty biopharma leaders share predictions for 2026 – from shifting dealmaking dynamics and Asia's rise as an innovation epicenter to new frontiers in oncology, obesity and cell therapy, and AI's operational reckoning.
When OSE Immunotherapeutics' board ousted CEO Nicolas Poirier in October 2025, it handed his successor a clear mandate: spend less, partner sooner and stop asking shareholders to wait.
Executives from Novo Nordisk, Ipsen, Astellas, Acadia and Flagship Pioneering agree: the dealmaking environment is improving but the calculus has changed. Flexible structures, sharper therapeutic focus, and the long shadow of patent cliffs and pricing policy are reshaping how partnerships get done.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company’s leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.
Boehringer Ingelheim is restructuring its therapeutic operations to push decision-making closer to brand teams while keeping R&D spending around 25% of revenues.
Immunis's secretome therapy showed 26% gait speed improvement in sarcopenic seniors, validating a longevity platform that sidesteps FDA's refusal to recognize aging as disease.